12:00 AM
Nov 12, 2012
 |  BC Week In Review  |  Company News  |  Deals

Arena, Ildong deal

Arena granted Ildong exclusive development and marketing rights to obesity drug Belviq lorcaserin in South Korea. Arena will receive $5 million up front and is eligible to receive $3 million upon Korean...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >